Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07138898 · ClinicalTrials.gov registry record · Phase 2
Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty
A Phase 2 study, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT07138898 is a Phase 2 study that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 80 participants.
The verdict
NCT07138898, a Phase 2 study, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the incidence of rheumatologic flares, changes in pain scores (VAS), changes in functional outcomes (PROMIS), wound complications, surgical site infections, and return trips to the operating room for rheumatology patients following shoulder replacements, comparing those who stop their immunosuppressants preoperatively for the same amount of time as suggested in the literature for hip and knee arthroplasty versus those who hold the medications for a shorter period of time preoperatively.
Interventions
- DRUG Methotrexate
- DRUG Azathioprine
- DRUG Leflunomide
- DRUG Hydroxychloroquine
- DRUG Sulfasalazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2025-12-12 |
| Est. Completion | 2028-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07138898
The ClinicalTrials.gov registry entry for NCT07138898 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Methotrexate is the first listed.
NCT07138898 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07138898 about?
NCT07138898 is a clinical study titled "Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty". The purpose of this study is to assess the incidence of rheumatologic flares, changes in pain scores (VAS), changes in functional outcomes (PROMIS), wound complications, surgical site infections, and return trips to the operating room for rheumatology patients following shoulder replacements, compar...
What is the current status of trial NCT07138898?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2025-12-12. Estimated completion is 2028-01.
What interventions are being tested in trial NCT07138898?
The interventions under investigation include: Methotrexate (DRUG), Azathioprine (DRUG), Leflunomide (DRUG), Hydroxychloroquine (DRUG), Sulfasalazine (DRUG).
Who is sponsoring clinical trial NCT07138898?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.